These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 31631034)
1. Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseases. Zhao L; Niu J; Lin H; Zhao J; Liu Y; Song Z; Xiang C; Wang X; Yang Y; Li X; Mohammadi M; Huang Z EBioMedicine; 2019 Oct; 48():462-477. PubMed ID: 31631034 [TBL] [Abstract][Full Text] [Related]
2. The FGFR D3 domain determines receptor selectivity for fibroblast growth factor 21. Gupte J; Yang L; Wu X; Weiszmann J; Hecht R; Lemon B; Lindberg R; Wang Z; Li Y J Mol Biol; 2011 May; 408(3):491-502. PubMed ID: 21392510 [TBL] [Abstract][Full Text] [Related]
3. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. Yang C; Jin C; Li X; Wang F; McKeehan WL; Luo Y PLoS One; 2012; 7(3):e33870. PubMed ID: 22442730 [TBL] [Abstract][Full Text] [Related]
4. Paracrine FGFs target skeletal muscle to exert potent anti-hyperglycemic effects. Ying L; Wang L; Guo K; Hou Y; Li N; Wang S; Liu X; Zhao Q; Zhou J; Zhao L; Niu J; Chen C; Song L; Hou S; Kong L; Li X; Ren J; Li P; Mohammadi M; Huang Z Nat Commun; 2021 Dec; 12(1):7256. PubMed ID: 34907199 [TBL] [Abstract][Full Text] [Related]
5. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Suzuki M; Uehara Y; Motomura-Matsuzaka K; Oki J; Koyama Y; Kimura M; Asada M; Komi-Kuramochi A; Oka S; Imamura T Mol Endocrinol; 2008 Apr; 22(4):1006-14. PubMed ID: 18187602 [TBL] [Abstract][Full Text] [Related]
6. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Hale C; Chen MM; Stanislaus S; Chinookoswong N; Hager T; Wang M; Véniant MM; Xu J Endocrinology; 2012 Jan; 153(1):69-80. PubMed ID: 22067317 [TBL] [Abstract][Full Text] [Related]
7. Heparin is essential for optimal cell signaling by FGF21 and for regulation of βKlotho cellular stability. An SJ; Mohanty J; Tome F; Suzuki Y; Lax I; Schlessinger J Proc Natl Acad Sci U S A; 2023 Feb; 120(7):e2219128120. PubMed ID: 36745784 [TBL] [Abstract][Full Text] [Related]
8. Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex. Foltz IN; Hu S; King C; Wu X; Yang C; Wang W; Weiszmann J; Stevens J; Chen JS; Nuanmanee N; Gupte J; Komorowski R; Sekirov L; Hager T; Arora T; Ge H; Baribault H; Wang F; Sheng J; Karow M; Wang M; Luo Y; McKeehan W; Wang Z; Véniant MM; Li Y Sci Transl Med; 2012 Nov; 4(162):162ra153. PubMed ID: 23197570 [TBL] [Abstract][Full Text] [Related]
9. A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys. Stanislaus S; Hecht R; Yie J; Hager T; Hall M; Spahr C; Wang W; Weiszmann J; Li Y; Deng L; Winters D; Smith S; Zhou L; Li Y; Véniant MM; Xu J Endocrinology; 2017 May; 158(5):1314-1327. PubMed ID: 28324011 [TBL] [Abstract][Full Text] [Related]
10. A unique FGF23 with the ability to activate FGFR signaling through both αKlotho and βKlotho. Wu X; Weiszmann J; Ge H; Baribault H; Stevens J; Hawkins N; Vonderfecht S; Gardner J; Gupte J; Sheng J; Wang M; Li Y J Mol Biol; 2012 Apr; 418(1-2):82-9. PubMed ID: 22370560 [TBL] [Abstract][Full Text] [Related]
11. Understanding the physical interactions in the FGF21/FGFR/β-Klotho complex: structural requirements and implications in FGF21 signaling. Yie J; Wang W; Deng L; Tam LT; Stevens J; Chen MM; Li Y; Xu J; Lindberg R; Hecht R; Véniant M; Chen C; Wang M Chem Biol Drug Des; 2012 Apr; 79(4):398-410. PubMed ID: 22248288 [TBL] [Abstract][Full Text] [Related]
12. Different roles of N- and C- termini in the functional activity of FGF21. Micanovic R; Raches DW; Dunbar JD; Driver DA; Bina HA; Dickinson CD; Kharitonenkov A J Cell Physiol; 2009 May; 219(2):227-34. PubMed ID: 19117008 [TBL] [Abstract][Full Text] [Related]
13. Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity. Agrawal A; Parlee S; Perez-Tilve D; Li P; Pan J; Mroz PA; Kruse Hansen AM; Andersen B; Finan B; Kharitonenkov A; DiMarchi RD Mol Metab; 2018 Jul; 13():45-55. PubMed ID: 29789271 [TBL] [Abstract][Full Text] [Related]
14. Uncoupling the Mitogenic and Metabolic Functions of FGF1 by Tuning FGF1-FGF Receptor Dimer Stability. Huang Z; Tan Y; Gu J; Liu Y; Song L; Niu J; Zhao L; Srinivasan L; Lin Q; Deng J; Li Y; Conklin DJ; Neubert TA; Cai L; Li X; Mohammadi M Cell Rep; 2017 Aug; 20(7):1717-1728. PubMed ID: 28813681 [TBL] [Abstract][Full Text] [Related]
15. Agonistic β-Klotho antibody mimics fibroblast growth factor 21 (FGF21) functions. Min X; Weiszmann J; Johnstone S; Wang W; Yu X; Romanow W; Thibault S; Li Y; Wang Z J Biol Chem; 2018 Sep; 293(38):14678-14688. PubMed ID: 30068552 [TBL] [Abstract][Full Text] [Related]
16. Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Itoh N Cell Tissue Res; 2010 Oct; 342(1):1-11. PubMed ID: 20730630 [TBL] [Abstract][Full Text] [Related]
17. The structural biology of the FGF19 subfamily. Beenken A; Mohammadi M Adv Exp Med Biol; 2012; 728():1-24. PubMed ID: 22396159 [TBL] [Abstract][Full Text] [Related]
18. Expression profile and overexpression outcome indicate a role for βKlotho in skeletal muscle fibro/adipogenesis. Phelps M; Stuelsatz P; Yablonka-Reuveni Z FEBS J; 2016 May; 283(9):1653-68. PubMed ID: 26881702 [TBL] [Abstract][Full Text] [Related]
19. Physiology and Endocrinology Symposium: FGF21: Insights into mechanism of action from preclinical studies. Antonellis PJ; Kharitonenkov A; Adams AC J Anim Sci; 2014 Feb; 92(2):407-13. PubMed ID: 24398833 [TBL] [Abstract][Full Text] [Related]
20. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Ogawa Y; Kurosu H; Yamamoto M; Nandi A; Rosenblatt KP; Goetz R; Eliseenkova AV; Mohammadi M; Kuro-o M Proc Natl Acad Sci U S A; 2007 May; 104(18):7432-7. PubMed ID: 17452648 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]